Novo Nordisk offers Diabetes Drug Ozempic for steep barglaurus
A box of Novo Nordisk in a pharmacy in London on March 8, 2024.
Hollie Adams | Reuters
Novo Nordisk On Monday it said that US patients with the Blockbuster diabetes treatment Ozempic offer less than half of its monthly list price, since the drug manufacturers are exposed to increasing political pressure to reduce prices in the country.
Patients can pay 499 US dollars in cash per month for three dose sizes from Ozempic. You can receive the price via platforms, including the official website of the drug, the patient aid program of Novo Nordisk and the recently direct-to-consumer online pharmacy of the company, from which the latter also sends the injection directly to the patients’ houses.
Ozempic and its weight loss -counter -item for 499 US dollars per month will also offer the drug savings from Gootrx, so that according to a publication by Novo Nordisk, more than 70,000 pharmacies nationwide are available.
“We got up of our consumer base for these coveted therapies, but millions of people still have adequate insurance protection,” said Wendy Barnes, CEO of Goodrx. “With this cooperation, we take a considerable step forward in our broader efforts to close the insurance gaps if the insurance is too short.”
The Cash Pay offer from Novo Nordisk expands access to eligible type 2 diabetes patients who have no insurance cover for weekly injection. In March, the company began offering Wegovy for half of its list price for the Americans paid in cash.
More CNBC health insurance
Ozempic’s list price before insurance and other discounts is almost 1,350 US dollars per month and has been a common goal of political and public setback in recent years. The new offer will take place after President Donald Trump sent separate letters to Novo Nordisk and 16 other drug makers in July and asked them to take measures to have proposed medication prices in the United States. He asked them to use models that sell medication directly to consumers or companies.
The efforts aim to provide more people Ozempic and Wegovy and at the same time ensure that patients use the brand medication instead of cheaper, compiled imitators. These medication exploded popularly popular in the case of a U.S. deficiency in Semaglutide, which has now been dissolved by Novo Nordisk, the active ingredient in both medicines.
While Ozempic is “well covered in the USA, we do not forget that there are some patients who can stand out for this vital medicine,” said Dave Moore, Executive Vice President of US Operations and Global Business Development at Novo Nordisk. “We believe that even a single patient has the need to turn potentially unsafe and not approved Knockoff alternatives, that’s too many.”
Eli Lilly has moved similarly to reduce the price of its popular obesity and diabetes medication for patients with money payment. The two companies are fighting to dominate the market for so-called GLP-1S, which mimic certain intestinal hormones to suppress the appetite and regulate blood sugar.
